Disease relevance of Shy-Drager Syndrome

• CONCLUSION: Our data indicate that the pressor effect of SMS-201-995 is independent of the sympathetic nervous system in patients with multiple system atrophy, but may suppress the adrenergic response to glucose ingestion in patients with progressive autonomic failure [1].
• Low doses of octreotide (0.2-0.4 micrograms/kg) had a pressor effect in all patients with progressive autonomic failure (n = 7), multiple system atrophy (n = 7), and diabetic autonomic neuropathy (n = 8), but not in patients with sympathotonic orthostatic hypotension (n = 6) [2].
• Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome [3].
• Subsensitivity to dopamine was observed in patients with Parkinson's disease, but supersensitivity in those with the Shy-Drager syndrome [4].
• Reactive microglia or macrophages expressing the histocompatibility glycoprotein HLA-DR were detected in many neurological diseases including Alzheimer's, Parkinson's, Pick's and Huntington's diseases, parkinsonism-dementia of Guam, amyotrophic lateral sclerosis, Shy-Drager syndrome, multiple sclerosis and AIDS encephalopathy [5].

High impact information on Shy-Drager Syndrome

• Effect of xamoterol in Shy-Drager syndrome [6].
• Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone [7].
• Autonomic hyperreflexia in pure progressive autonomic failure: a case report [8].
• Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome [9].
• Shy-Drager syndrome with abnormal respirations and antidiuretic hormone release [10].

Chemical compound and disease context of Shy-Drager Syndrome

• In a controlled trial lisuride, an ergolene derivative with dopamine receptor agonist properties was given maximum tolerated doses (2.4 mg/day) to seven patients with multiple system atrophy with autonomic failure (Shy-Drager syndrome) [11].
• Patients with progressive autonomic failure with multiple system atrophy show a severely blunted response of plasma arginine vasopressin to the stimulus of head-up tilt [12].
• The management of Shy-Drager syndrome with propantheline and intermittent self-catheterization: a case report [13].
• Indomethacin and propranolol combined treatment for Shy-Drager syndrome [14].
• Compared to control subjects supersensitivity to noradrenaline was observed both in patients with Parkinson's disease and, to a greater extent, in those with the Shy-Drager syndrome [4].

Biological context of Shy-Drager Syndrome

• We investigated the effect of xamoterol in five patients with Shy-Drager syndrome (SDS) in relation to their prevailing sympathetic nerve activity and sensitivity of beta-adrenoceptors and the change in circadian variation of blood pressure [6].
• Urological aspects of the Shy-Drager syndrome: a urodynamic and telemetric investigation. Incontinence treatment by electrical pacemaker and prenalterol [15].
• Heart rate decreased during pressor responses to noradrenaline in control subjects and patients with Parkinson's disease, but increased in those with the Shy-Drager syndrome [4].

Anatomical context of Shy-Drager Syndrome

• A patient with Shy-Drager syndrome exhibited a partial defect in antidiuretic hormone (ADH) release, and cluster breathing, an indication of pontomedullary respiratory center damage, with a normal CO2 response curve [10].
• Multiple system atrophy (MSA) is a degenerative disease of the central nervous system with three components, usually variously expressed: nigrostriatal degeneration (NSD), olivopontocerebellar atrophy (OPCA) and Shy-Drager syndrome of autonomic system dysfunction (SDS) [16].

Gene context of Shy-Drager Syndrome

• Tuberoinfundibular dopaminergic system (TIDA) together with anterior pituitary dopamine receptor was evaluated in 9 patients with Shy-Drager syndrome (SDS) through the responses of serum growth hormone (GH) and prolactin (PRL) to dopaminergic stimulation or dopamine receptor inhibition [17].
• METHODS AND RESULTS: We studied incremental doses of the COMT inhibitor entacapone, the sympathetic stimulant yohimbine, and placebo in 7 patients with multiple system atrophy (Shy Drager syndrome) [18].
• Postural changes in plasma renin activity and responses to vasoactive drugs in a case of Shy-Drager syndrome [19].
• Previous investigations have demonstrated that the postural stimulation of arginine vasopressin (AVP) release is reduced in patients with Shy-Drager syndrome [20].
• The distribution of intra-axonal corpora amylacea (IACA) in the CNS was studied in 2 cases of ALS, a hepatic encephalopathy and a Shy-Drager syndrome [21].

References